Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis

INTRODUCTION: The cost-effectiveness of different biologic therapies can be an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this study was to compare drug and adverse event costs and cost per successful clinical response with tocili...

Descripción completa

Detalles Bibliográficos
Autores principales: Best, Jennie H., Vlad, Steven C., Pei, Jinglan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021858/
https://www.ncbi.nlm.nih.gov/pubmed/31907758
http://dx.doi.org/10.1007/s40744-019-00191-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021858/
https://www.ncbi.nlm.nih.gov/pubmed/31907758
http://dx.doi.org/10.1007/s40744-019-00191-6

Ejemplares similares